Genetic Modulation of Blood and Vascular Glycosylation
Genetic Modulation of Blood and Vascular Glycosylation
批准号:
8207945
负责人:
NISSI Mary VARKI
金额:
$227.74万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2013-12-31
关键词:
AffectBinding ProteinsBiologicalBiologyBloodBlood CellsBlood VesselsCaenorhabditis elegansCardiovascular systemCell surfaceCellsCellular StructuresCollaborationsCultured CellsDermatan SulfateDetectionDiseaseDrosophila genusEmbryoEndothelial CellsEndotheliumExtracellular SpaceGene SilencingGenesGeneticGlycocalyxGlycoproteinsGlycosaminoglycansHealthHemostatic functionHeparitin SulfateHumanHyaluronanHyaluronidaseImmune responseImmune systemIn VitroInvertebratesKnowledgeLaboratoriesLectinLeukocytesMammalsMediatingModelingMorphologic artifactsMusNucleic AcidsOligosaccharidesOrganismPathologicPatternPhenotypePhysiologicalPlasma CellsPlasma ProteinsPolysaccharidesProcessProteinsRegulationResearch Project GrantsRoleSaccharomycesSialic AcidsSignal TransductionStructureSystemTechnologyTissuesTransgenic OrganismsVariantVascular Systemangiogenesisbeta-galactosidecell typedermatan sulfate proteoglycanextracellulargenetic manipulationglycosylationimmune functionmigrationoverexpressionprogramsprotein degradationreceptorsialic acid binding Ig-like lectinsugar
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Glycan chains are major components of cells and extracellular molecules, with a complexity rivalling that of nucleic acids and proteins. This program continues to focus on two major types of anionic glycans at the outermost aspects of the cell surface glycocalyx - Sialic Acids (Sias) and the Glycosaminoglycan (GAG) chains Hyaluronan (HA), Heparan sulfate (HS) and Chondrotin suflate/Dermatan sulfate (CS/DS). The structures of sialylated N- and O-glycans of blood cell and plasma glycoproteins are well described. Specific glycan-binding proteins differentially recognize these Sias, including CD33-related Siglecs (l-type lectins with cytosolic signaling motifs, on specific blood cell types) (Project 2). Some beta-galactoside-specific lectins detect the selective absence of certain Sias on proteins involved in hemostasis and immune function, affecting their regulation and turnover (Project 1). The GAG chains of HS and CS/DS proteoglycans regulate multiple processes in endothelial biology, including angiogenesis and leukocyte migration (Project 3). Fragments of HA generated by specific hyaluronidases can also ligate pattern detection receptors such as TLRs (Project 4). Most physiologic and pathological roles of Sias and GAGs are not evident in cultured cells, but must be explored in the intact organism - and this complexity of mammalian glycans is not well represented in model invertebrates. Thus, the central theme of this proposal is state-of-the-art genetic manipulation of Sias, GAG chains, and some of their cognate binding proteins in the mouse. When systemic gene inactivation models are non-viable or have confusing phenotypes, we will selectively inactivate mouse. genes in a cell type-specific and developmentally-regulated manner. In some instances, transgenic overexpression of genes is appropriate to answer specific questions. This approach allows a specific focus on glycans and glycan-binding proteins of blood cells, endothelium, and plasma proteins. Over the past 10 years, we have assembled and sustained a highly interactive team of experts to analyze the consequences of such genetic manipulations on the structure and function of hemostatic, immune and vascular systems, focusing on functional consequences on plasma protein turnover, angiogenesis, and the leukocyte-mediated immune responses. Many more opportunities for intellectual and practical collaborations and synergies have also emerged. These studies will reveal many important functions for glycans in health and disease.
期刊论文(90)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pone.0072421
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Kim MY, Muto J, Gallo RL]
通讯作者:
Gallo RL
Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.
肝素的抗炎作用需要氨基葡萄糖 6-O-硫酸化,并通过 L-和 P-选择素的阻断介导。
DOI:
10.1172/jci14996
发表时间:
2002
期刊:
The Journal of clinical investigation.
影响因子:
--
作者:
[Wang,Lianchun, Brown,JillianR, Varki,Ajit, Esko,JeffreyD]
通讯作者:
Esko,JeffreyD
A mouse strain defective for alphabeta versus gammadelta T cell lineage commitment.
Alphabeta 与 gammadelta T 细胞谱系定型存在缺陷的小鼠品系。
DOI:
10.1093/intimm/dxf067
发表时间:
2002
期刊:
International immunology
影响因子:
4.4
作者:
[Mertsching,Elisabeth, Wurster,AndreaL, Katayama,Carol, Esko,Jeffrey, Ramsdell,Fred, Marth,JameyD, Hedrick,StephenM]
通讯作者:
Hedrick,StephenM
Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis.
细胞表面唾液酸不影响 CD22 与 CD45 和表面 IgM 的主要相互作用,也不影响组成型 CD22 内吞作用的速率。
DOI:
10.1093/glycob/cwh126
发表时间:
2004
期刊:
Glycobiology
影响因子:
4.3
作者:
[Zhang,Mai, Varki,Ajit]
通讯作者:
Varki,Ajit
The elusive role of heparan sulfate in Toxoplasma gondii infection.
硫酸乙酰肝素在弓形虫感染中的难以捉摸的作用。
DOI:
10.1016/j.molbiopara.2004.11.007
发表时间:
2005
期刊:
Molecular and biochemical parasitology.
影响因子:
--
作者:
[Bishop,JosephR, Esko,JeffreyD]
通讯作者:
Esko,JeffreyD
共 30 条
Histology Core
-
批准号:7406288
-
项目类别:
-
资助金额:$20.44万
-
财政年份:2007
-
负责人:NISSI Mary VARKI
-
依托单位:
Histopathology Core
-
批准号:7509278
-
项目类别:
-
资助金额:$18.64万
-
财政年份:2007
-
负责人:NISSI Mary VARKI
-
依托单位:
Core--Histology
-
批准号:6704468
-
项目类别:
-
资助金额:$13.12万
-
财政年份:2003
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6653289
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2002
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6580373
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2002
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6599263
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2002
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6592146
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2002
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6579409
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2002
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6450325
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6501406
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2001
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6438197
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6576201
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6395856
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2000
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6316517
-
项目类别:
-
资助金额:$10.6万
-
财政年份:2000
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6296433
-
项目类别:
-
资助金额:$14.5万
-
财政年份:1999
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOLOGY AND IMMUNOHISTOCHEMISTRY
-
批准号:6192436
-
项目类别:
-
资助金额:$10.6万
-
财政年份:1999
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6105305
-
项目类别:
-
资助金额:$14.5万
-
财政年份:1999
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6296443
-
项目类别:
-
资助金额:$13.03万
-
财政年份:1998
-
负责人:NISSI Mary VARKI
-
依托单位:
Genetic Modulation of Blood and Vascular Glycosylation
-
批准号:8039939
-
项目类别:
-
资助金额:$227.74万
-
财政年份:1998
-
负责人:NISSI Mary VARKI
-
依托单位:
CORE--HISTOPATHOLOGY FACILITY
-
批准号:6270622
-
项目类别:
-
资助金额:$13.03万
-
财政年份:1998
-
负责人:NISSI Mary VARKI
-
依托单位:
海外基金